{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05815199",
            "orgStudyIdInfo": {
                "id": "23-00124"
            },
            "organization": {
                "fullName": "NYU Langone Health",
                "class": "OTHER"
            },
            "briefTitle": "E-cigarettes for Harm Reduction Among Smokers With Serious Mental Illness",
            "officialTitle": "Effectiveness and Impact of Counseling Enhanced Using Electronic Cigarettes for Harm Reduction in People With Serious Mental Illness",
            "therapeuticArea": [
                "Other"
            ],
            "study": "e-cigarettes-for-harm-reduction-among-smokers-with-serious-mental-illness"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-11-13",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-04-04",
            "studyFirstSubmitQcDate": "2023-04-04",
            "studyFirstPostDateStruct": {
                "date": "2023-04-18",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-29",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-31",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "NYU Langone Health",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "In this open-label, randomized controlled trial study, participants who smoke combustible cigarettes (CC) and are diagnosed with Serious Mental Illness (SMI) will be randomized in two arms to receive harm-reduction counseling and Ecological Momentary Intervention text messaging (EMI) along with either e-cigarettes (EC) or nicotine replacement therapy (NRT) such as patch and lozenges to compare the efficacy in CC smoking reduction."
        },
        "conditionsModule": {
            "conditions": [
                "Cigarette Smoking"
            ],
            "keywords": [
                "E-cigarettes",
                "Harm reduction",
                "Cigarette smoking",
                "Serious mental illness"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 60,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "E-cigarettes (EC)",
                    "type": "EXPERIMENTAL",
                    "description": "Adult cigarette smokers with a SMI diagnosis randomized to the EC arm will receive NRT including nicotine patches and lozenges. Participants will also receive telehealth motivational counseling during the intervention period of 8 weeks.",
                    "interventionNames": [
                        "Other: E-cigarette (EC)",
                        "Behavioral: Harm-Reduction Counseling",
                        "Behavioral: Ecological Momentary Intervention (EMI) Text Messaging"
                    ]
                },
                {
                    "label": "Nicotine Replacement Therapy (NRT)",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Adult cigarette smokers with a SMI diagnosis randomized to the NRT arm will receive NRT including nicotine patches and lozenges gum. Participants will also receive telehealth motivational counseling during the intervention period of 8 weeks.",
                    "interventionNames": [
                        "Other: Nicotine Replacement Therapy (NRT)",
                        "Behavioral: Harm-Reduction Counseling",
                        "Behavioral: Ecological Momentary Intervention (EMI) Text Messaging"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "E-cigarette (EC)",
                    "description": "Fixed dose. Participants are to use the EC as replacement for smoking combustible cigarettes. Participants will vape the EC.",
                    "armGroupLabels": [
                        "E-cigarettes (EC)"
                    ],
                    "otherNames": [
                        "NJOY Ace or NJOY Daily Electronic Cigarette"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Nicotine Replacement Therapy (NRT)",
                    "description": "Includes nicotine patches and lozenges. NRT use recommendations will follow the guidelines of the product, e.g. one patch per day.",
                    "armGroupLabels": [
                        "Nicotine Replacement Therapy (NRT)"
                    ]
                },
                {
                    "type": "BEHAVIORAL",
                    "name": "Harm-Reduction Counseling",
                    "description": "At baseline, after randomization, participants will receive their first telehealth session (20\\~25 minutes) from a counselor trained in motivational interviewing, harm reduction, and smoking cessation. Up to five additional sessions will be delivered, 15\\~20 minutes each.",
                    "armGroupLabels": [
                        "E-cigarettes (EC)",
                        "Nicotine Replacement Therapy (NRT)"
                    ]
                },
                {
                    "type": "BEHAVIORAL",
                    "name": "Ecological Momentary Intervention (EMI) Text Messaging",
                    "description": "EMI can be defined as delivering tailored interventions via electronic messages (i.e., regular text messages) that include personalized feedback based on real-time assessment responses and other contextual factors. EMI will take place throughout the intervention period.",
                    "armGroupLabels": [
                        "E-cigarettes (EC)",
                        "Nicotine Replacement Therapy (NRT)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Percentage of Participants who Achieve a 100% Reduction in Cigarettes Per Day (CPD) by Week 4",
                    "description": "Measured via self-report (daily diary about smoking behavior) and verified by exhaled carbon-monoxide (eCO) level (\\< 6 ppm).",
                    "timeFrame": "Up to Week 4"
                },
                {
                    "measure": "Percentage of Participants who Achieve a 100% Reduction in Cigarettes Per Day (CPD) by Week 8",
                    "description": "Measured via self-report (daily diary about smoking behavior) and verified by exhaled carbon-monoxide (eCO) level (\\< 6 ppm).",
                    "timeFrame": "Up to Week 8"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Percentage of Participants who Achieve a 100% Reduction in Cigarettes Per Day (CPD) by Week 12",
                    "description": "Measured via self-report (daily diary about smoking behavior) and verified by exhaled carbon-monoxide (eCO) level (\\< 6 ppm).",
                    "timeFrame": "Up to Week 12"
                },
                {
                    "measure": "Self-Reported Percent Change in CPD from Baseline to Week 8",
                    "description": "Measured via self-report (daily diary about smoking behavior).",
                    "timeFrame": "Baseline, Week 8"
                },
                {
                    "measure": "Self-Reported Percent Change in CPD from Baseline to Week 12",
                    "description": "Measured via self-report (daily diary about smoking behavior).",
                    "timeFrame": "Baseline, Week 12"
                },
                {
                    "measure": "Change in American Thoracic Questionnaire Score from Baseline to Week 12",
                    "description": "8-item questionnaire assessing general thoracic pain. Items are rated on a Likert scale from 1 (never) to 5 (every day). The total score is the sum of responses and ranges from 8-40; higher scores indicate more severe impact of general thoracic pain.",
                    "timeFrame": "Baseline, Week 12"
                },
                {
                    "measure": "Change in Symptom Check Questionnaire Score from Baseline to Week 12",
                    "description": "9-item assessment of chronic obstructive pulmonary disease (COPD) symptoms. Each item is marked as either \"yes\" or \"no.\" The total score is the number of \"yes\" responses and ranges from 0-9; higher scores indicate more severe COPD symptoms.",
                    "timeFrame": "Baseline, Week 12"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Currently smokes 5 or more CPD\n* Willingness and ability to provide informed consent\n* Age of at least 21 years\n* Has SMI diagnosis (such as Schizophrenia, Schizoaffective disorders, Bipolar disorder, Depressive disorders, Trauma and stressor related disorders etc.) as determined using the MINI tool\n* Interested in reducing CC smoking but not necessarily trying to quit\n* Own a mobile phone or have regular access to a mobile phone\n* Able to provide an additional contact to improve follow-up rates\n\nExclusion Criteria:\n\n* Is pregnant or breastfeeding\n* Used tobacco other than CC in the past 2 weeks (e.g., EC, cigarillo)\n* Currently engaged in an attempt to quit CC\n* Change in dose of their psychotropic medication(s) in the last 30 days\n* Meeting DSM-V criteria for current alcohol or substance use disorder except for nicotine use disorder and active mild alcohol or substance use disorders.\n* Past month suicidal ideation/suicide attempt and/or psychiatric hospitalization in the last 30 days",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "21 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Omar El-Shahawy",
                    "role": "CONTACT",
                    "phone": "646-501-3587",
                    "email": "Omar.ElShahawy@nyulangone.org"
                },
                {
                    "name": "Izamar Gallardo Castillo",
                    "role": "CONTACT",
                    "phone": "646-501-3602",
                    "email": "Izamar.gallardocastillo@nyulangone.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Omar El-Shahawy",
                    "affiliation": "NYU Langone Health",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "NYU Langone Health",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10016",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request or for individual participant data meta-analysis beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data or researcher who provides a methodologically sound proposal executes a data use agreement with NYU Langone Health. Requests may be directed to: Omar.ElShahawy@nyulangone.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.",
            "timeFrame": "Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.",
            "accessCriteria": "The investigator who proposed to use the data or researchers who provide a methodologically sound proposal will be granted access upon reasonable request or for individual participant data meta-analysis. Requests should be directed to Omar.ElShahawy@nyulangone.org. To gain access, data requestors will need to sign a data access agreement."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "asFound": "Mental Illness",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009538",
                    "term": "Nicotine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005731",
                    "term": "Ganglionic Stimulants"
                },
                {
                    "id": "D000001337",
                    "term": "Autonomic Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018722",
                    "term": "Nicotinic Agonists"
                },
                {
                    "id": "D000018679",
                    "term": "Cholinergic Agonists"
                },
                {
                    "id": "D000018678",
                    "term": "Cholinergic Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12478",
                    "name": "Nicotine",
                    "asFound": "Assess",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4029",
                    "name": "Central Nervous System Stimulants",
                    "relevance": "LOW"
                },
                {
                    "id": "M20796",
                    "name": "Nicotinic Agonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20758",
                    "name": "Cholinergic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "CNSSti",
                    "name": "Central Nervous System Stimulants"
                }
            ]
        }
    },
    "hasResults": false
}